-
-
Overview
-
Please contact us at for specific academic pricing.
Background
Description:IC50: 170 nm (CREBBP/EP300)A bromodomain is an approximately 110 amino acid protein domain that recognizes monoacetylated lysine residues such as those on the N-terminal tails of histones. Members of the BET family (Bromodomain and extraterminal domain family) have been implicated as targets in human cancer. Inhibitors of BET have shown therapeutic effects in multiple models of hematological malignancies as well as solid tumors. SGC have developed an inhibitor, I-CBP112, against the CREBBP and EP300 Bromodomains.In vitro: A CREBBP/EP300-selective chemical probe from a completely different structural class which was also developed by the SGC is I-CBP112. I-CBP112 has an IC50 value of 170 nm in the CREBBP AlphaScreen assay, and is selective against the bromodomain proteins ATAD2, BAZ2B, BRD2(BD2), BRD4 (BD1), PB1(BD5), PCAF, PHIP(BD2), TRIM24/TIF-1a. In U2OS cells no significant cytotoxicity up to 50 mm was found. Similar to bromosporine 129, data related to SGCCBP30 and I-CBP112 are reported on the SGC homepage exclusively [1]. In vivo: Currently, I-CBP112 is still in the in-vitro investigation, and no animal in-vivo study is on-going. Clinical trial: I-CBP112 is currently in the preclinical development and no clinical trial is ongoing.
[1] Gallenkamp D, Gelato KA, Haendler B, Weinmann H. Bromodomains and their pharmacological inhibitors. ChemMedChem. 2014;9(3):438-64.
-
- Properties
-
Overview